UNSPSC 51391705: Bambuterol

This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y1850G1OVC. European Medicines Agency schedules Bambuterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06095MIG. Bambuterol generally arises in the molecular formula C18H29N3O5.

UNSPSC 51391705 Bambuterol is a Commodity code that nominally identifies a specific bronchodilator pharmaceutical product, but recent state and local procurement activity under this code shows minimal relevance to the code's stated scope. The single recent opportunity in the dataset—Seminole County, Florida's IFB60459723LAS—solicits naloxone and drug deactivation systems for community health initiatives, not bambuterol. This mismatch suggests either a tagging error in the state or local procurement system or that the code is used inconsistently across jurisdictions. The opportunity does reflect state and local demand for emergency pharmaceutical and harm-reduction supplies, with Seminole County seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding.

The geographic reach of this code is limited to the single documented posting in Florida. Seminole County's IFB, posted June 30, 2026, with a response deadline of July 26, 2023 (note the date inconsistency in the source), targets quarterly deliveries to the Seminole County Community Health Building in Sanford. The procurement includes standard state and local compliance requirements—drug-free workplace certification, E-Verify validation, workers' compensation and general liability insurance—and allows for a two-year initial term with a one-year renewal option. Because the code shows no other recent state and local opportunities and the single documented solicitation addresses products outside bambuterol's pharmaceutical class, pursuit under this code warrants verification that the code is correctly assigned to intended product lines before bid investment.